Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
MISSION Trial – A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens
Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer
Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors
Mechanisms of Acquired Resistance to AZD9291, a Mutation-Selective, Irreversible EGFR Inhibitor
A Prognostic Model to Predict Mortality among Non-Small Cell Lung Cancer Patients in the U.S. Military Health System
Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS mutant lung cancer.
Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma
The lASLC Lung Cancer Staging Project
Soy Isoflavones Promote Radioprotection of Normal Lung Tissue by Inhibition of Radiation-Induced Activation of Macrophages and Neutrophils
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer patientswith leptomeningeal carcinomatosis
Utilization of hyperfractionated radiation in small cell lung cancer and its impact on survival.
Changes in Pulmonary Function Following Image Guided Stereotactic Lung Radiotherapy
Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas
Treatment Outcomes in Stage I Lung Cancer
EGFR MutationImpact on DefinitiveConcurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma
Role of postoperative radiotherapy in non-localized thymoma – Propensity-matched analysis of Surveillance, Epidemiology, and End Results (SEER) database